Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Medtronic (NYSE:MDT) wants NuVasive (NSDQ:NUVA) to pay royalties and interest on sales of spinal implants that a jury found to infringe Medtronic patents last year. The motion follows Medtronic’s September win, when a California jury awarded the med-tech titan $101 million after deciding that San Diego-based NuVasive wilfully infringed on Medtronic’s patents.
Shares of Boston Scientific (NYSE:BSX) are enjoying a modest gain today after Moody’s Investors Service (NYSE:MCO) upgraded its debt rating. The ratings agency said it believes BSX stock is less risky now that the Natick, Mass.-based medical device giant has reduced its debt load and introduced new products into its pipeline, according to Moody’s analyst Diana Lee.
The FDA’s neurological devices panel will review clinical data from trials of Stryker’s (NYSE:SYK) Wingspan brain stent system next month, aiming to address harsh criticisms and public petitions urging the agency to recall the device. The panel plans to consider pre-market and post-market data about the device, including the Gateway PTA balloon catheter and stent delivery system, to address concerns that Wingspan may lead to heightened risk of stroke or death.